Avid, Ampersand

Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital Partners is pulling out its life sciences checkbook once again. | CDMO Avid has agreed to be acquired by funds managed by Ampersand and GHO Capital Partners in an all-cash deal worth $1.
GHO and Ampersand Capital to acquire Avid Bioservices
The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a 13.
GHO Capital, Ampersand Capital to buy Avid Bioservices in $1.1bn deal
GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at around $1.1 billion. Avid provides development and manufacturing services to biotechnology and pharmaceutical companies. It is based in Tustin, California.
Avid Bioservices to be acquired for $1.1B in cash by GHO, Ampersand
Avid Bioservices (NASDAQ:CDMO) has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at around $1.1B. Under the deal,
Avid Bioservices to be taken private by GHO, Ampersand in $1.1 billion deal
Avid Bioservices said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion. GHO and Ampersand have offered $12.
Avid Bioservices to be Acquired in $1.1 Billion Deal
Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization,
Avid Bioservices: Take-Private Deal At A Reasonable Price, Maintaining Buy
We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about 1Q25 closing. Read more here.
Avid Bioservices to Go Private in $1.1 Billion Deal
Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move forward as a private company under new owners.
GlobalData on MSN4d
Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
FiercePharma5d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Business Wire2d
CDMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avid Bioservices, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...
Los Angeles Times2d
Tustin-based Biotech Company Avid Bioservices Inc. To Go Private in $850M Deal
Funds managed by GHO Capital Partners LLP and Ampersand Management LLC agreed to acquire the company, and it will continue ...
Avid Bioservices downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
MyChesCo on MSN5d
Resolian Announces Leadership Changes Amid Global Expansion
Bioanalytical contract research organization Resolian has announced significant leadership changes as it continues its global expansion. Rob Stachlewitz has been named the new Chief Executive Officer, ...